Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.58 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.58 |
| ▸ | CALCR | P30988 | 4/20 | 0.57 |
| ▸ | BACE1 | P56817 | 3/20 | 0.56 |
| ▸ | GLP1R | P43220 | 4/20 | 0.54 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.54 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30432084 | 0.89 | BACE1 (0.61) | CRHR1CRHR2CALCRBACE1GLP1R | |
| SCHEMBL30607339 | 0.89 | CRHR1 (0.63) | CRHR1CRHR2CALCRGLP1RVIPR1 | |
| SCHEMBL30680637 | 0.87 | BACE1 (0.58) | BACE1GLP1RVIPR1BACE2 | |
| SCHEMBL31307253 | 0.87 | CRHR1 (0.49) | CRHR1CRHR2CALCRBACE1GLP1R | |
| SCHEMBL29463758 | 0.87 | CALCR (0.57) | CRHR1CRHR2CALCRBACE1GLP1R | |
| SCHEMBL30262081 | 0.87 | CALCR (0.59) | CRHR1CRHR2CALCRGLP1RKEAP1 | |
| Aviptadil SCHEMBL30969141 | 0.86 | VIPR1 (0.72) | CRHR1CRHR2CALCRGLP1RVIPR1 | |
| Vasoactive Intestinal Peptide SCHEMBL3041046 | 0.86 | VIPR1 (0.72) | CRHR1CRHR2CALCRGLP1RVIPR1 | |
| SCHEMBL31182789 | 0.86 | GLP1R (0.60) | GLP1RVIPR1VIPR2KEAP1 | |
| SCHEMBL29496487 | 0.86 | F2 (0.53) | CALCRBACE1GLP1RBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153783-A1 | MITOCHONDRIA-TARGETING COMPOUND AND COMPOSITION COMPRISING SAME FOR TREATING OR PREVENTING AGING-RELATED DISEASES | FUSION BIOTECHNOLOGY CO., LTD. (KR) | 2022-05-19 | — | — | US | claimed |
| US-20260097092-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA-TARGETING COMPOUND AS ACTIVE INGREDIENT FOR TREATING MACULAR DEGENERATION | ULSAN NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-04-09 | — | — | US | disclosed |
| WO-2024063223-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA-TARGETING COMPOUND AS ACTIVE INGREDIENT FOR TREATING MACULAR DEGENERATION | 울산과학기술원 | 2024-03-28 | — | — | WO | disclosed |
| US-20220153783-A1 | MITOCHONDRIA-TARGETING COMPOUND AND COMPOSITION COMPRISING SAME FOR TREATING OR PREVENTING AGING-RELATED DISEASES | FUSION BIOTECHNOLOGY CO., LTD. (KR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097092-A1 | PHARMACEUTICAL COMPOSITION CONTAINING MITOCHONDRIA-TARGETING COMPOUND AS ACTIVE INGREDIENT FOR TREATING MACULAR DEGENERATION | ARG2, NLN, RHOT2 | CRHR1 3979/4885CRHR2 3875/4885CALCR 2789/4885 |
| US-20220153783-A1 | MITOCHONDRIA-TARGETING COMPOUND AND COMPOSITION COMPRISING SAME FOR TREATING OR PREVENTING AGING-RELATED DISEASES | TFAM, HSPA9, AIFM1 | CRHR1 4581/4885CRHR2 4509/4885CALCR 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.